| Literature DB >> 18047650 |
Annette A Harte1, George D Baxter, Jacqueline H Gracey.
Abstract
BACKGROUND: Traction is commonly used for the treatment of low back pain (LBP), predominately with nerve root involvement; however its benefits remain to be established. The aim of this study was to test the feasibility of a pragmatic randomized controlled trial to compare the difference between two treatment protocols (manual therapy, exercise and advice, with or without traction) in the management of acute/sub acute LBP with 'nerve root' involvement.Entities:
Mesh:
Year: 2007 PMID: 18047650 PMCID: PMC2217540 DOI: 10.1186/1471-2474-8-118
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Clinical trial procedure.
Traction parameters: nerve root patients
| Traction parameter | Recommended guidelines (Harte et al 2005) |
| Traction bed | Split table motorized traction unit |
| Traction Position | Fowler position (hips and knees flexed to 90 supported on stool |
| Traction Weight | 5 – 60 kg |
| Traction duration | 10 – 20 min each session |
| Traction Frequency | 2 – 3 times per week |
Baseline demographics for both groups
| LT group (n = 16 | MT group (n = 14) | |
| 45.25 (7.99) | 42.79 (12.09) | |
| Male | 37.5 (6) | 42.9 (6) |
| Female | 62.5 (10) | 57.1 (8) |
| In paid employment | 68.8 (11) | 78.6 (11) |
| Not in paid employment | 31.5 (5) | 21.4 (3) |
| Heavy manual work | 25 (4) | 35.7 (5) |
| Light work – desk/supervisory | 31.3 (5) | 28.6 (4) |
| Homemaker | 1.8 (3) | 21.4 (3) |
| Professional | 12.5 (2) | 7.1 (1) |
| Retired | 6.3 (1) | 7.1 (1) |
| Incapacity benefit | 6.3 (1) | 0 |
| Not applicable | 31.5 (5) | 14.3 (2) |
| At work | 43.8 (7) | 42.9 (6) |
| Off work due to LBP | 25 (4) | 42.9 (6) |
| 6.5 (4.8) | 6 (4) | |
| None | 81.3 (13 | 42.9 (6) |
| 1–3 | 6.3 (1) | 42.9 (6) |
| Constant LBP | 12.5 (2) | 14.3 (2) |
| No episodes | 81.3 (13) | 35.7 (5) |
| 3–6 months | 0 | 35.7 (5) |
| 7–12 months | 6.3 (1) | 7.1 (1) |
| >1 year | 0 | 7.1 (1) |
| Constant LBP | 12.5 (2) | 14.3 (2) |
| Yes | 12.5 (2) | 14.3 (2) |
| No | 50 (8) | 50 (8) |
| Not applicable | 37.5 (6) | 28.6 (4) |
| 62.5 (10) | 35.7 (5) | |
| 18.6 (3) | 21.4 (3) | |
| Current smoker | 25 (4) | 28.6 (4) |
| Past smoker | 6.3 (1) | 21.4 (3) |
| None smoker | 68.8 (11) | 50 (7) |
| Reflex – reduced/absent | 18.8 (3) | 35.7 (5) |
| Muscle power – reduced/absent | 37.5 (6) | 50 (7) |
| Sensation – decreased/hypersensitive | 18.8 (3) | 28.6 (4) |
| SLR – restricted and reproducing leg pain | 100 (16) | 78.6 (11) |
| Crossed SLR | 6.3 (1) | 21.4 (3) |
| RMDQ | 10 (4.5) | 11.5 (8.5) |
| MPQ-PRI | 20.5 (9) | 29 (20) |
| ALBPSQ | 104 (42.5) | 112 (49) |
| SF36 Physical component score (PCS) | 31 (3.6) | 36.1 (23.4) |
| SF36 Mental component score (MCS) | 46.5 (17.2) | 47.3 (21.3) |
| VAS back pain | 5 (4.5) | 5 (4.5) |
| VAS leg pain | 7 (3.5) | 5.6 (3.5) |
Figure 2Consort flow diagram.
Figure 3Median score for RMDQ at follow up points.
Figure 4Median score for MPQ – PRI at follow up points.
Figure 5Median score for SF36 physical component score at follow up points.
Figure 6Median score for SF36 mental component score at follow up points.
Outcome scores at baseline, post treatment, 3 and 6 months follow up for completers and intention to treat analysis
| LT Group (n = 13) Median (IQR) | MT Group (n = 10) Median (IQR) | LT Group (n = 16) Median (IQR) | MT Group (n = 14) Median (IQR) | |
| RMDQ baseline | 10 (4.5) | 11.5 (8.5) | 10 (4.5) | 11.5 (8.5) |
| after | 4 (3) | 1.5 (9.5) | 4 (5.8) | 4 (10.3) |
| 3 months | 2 (8.5) | 1 (11.3) | 4.5 (10.8) | 1 (10.5) |
| 6 months | 4 (9.5) | 1.5 (6.8) | 4.5 (15.3) | 2.5 (14) |
| MPQ-PRI baseline | 20.5 (9) | 29 (20) | 20.5 (9) | 29 (20) |
| after | 2 (7.5) | 9 (16.3) | 4 (15.3) | 12 (16.5) |
| 3 months | 4 (11) | 1 (23) | 6 (16.5) | 6 (21) |
| 6 months | 5 (16.5) | 3 (20.3) | 10 (20.5) | 6.5 (21) |
| SF36 PCS baseline | 31 (3.6) | 36.1 (23.4) | 31 (3.6) | 36.1 (23.4) |
| after | 43.9 (13.4) | 46.2 (24.1) | 38.5 (16.2) | 41.1 (21.1) |
| 3 months | 46.3 (17.9) | 45.9 (27.4) | 41.6 (18.6) | 43.2 (24) |
| 6 months | 42.7 (16.7) | 50.5 (23) | 40 (15) | 46 (22) |
| SF36 MCS baseline | 46.5 (17.2) | 41.2 (25.8) | 46.5 (17.2) | 41.2 (25.8) |
| after | 53.2 (19.3) | 50.4 (27) | 52 (26.1) | 48.3 (25.6) |
| 3 months | 55.2 (24.2) | 49.5 (27.7) | 49.5 (25.8) | 47.3 (21.3) |
| 6 months | 52.6 (18.4) | 55 (15) | 51.8 (23) | 49.8 (19.8) |
Total change scores for outcomes from baseline to follow up points for completers and intention to treat analysis
| LT Group (n = 13) Median (IQR) | MT Group (n = 10) Median (IQR) | LT Group (n = 16) Median (IQR) | MT Group (n = 14) Median (IQR) | |
| Total change score RMDQ | ||||
| baseline to post treatment | 5.5 (4.5) | 3 (5.5) | 4.5 (7.3) | 3 (8) |
| baseline to 3 months | 6 (7.5) | 5 (15.8) | 6 (7.8) | 5 (15) |
| baseline to 6 months | 7 (7) | 5.5 (11.3) | 4 (12.3) | 3 (12.3) |
| Total change score MPQ-PRI | ||||
| baseline to post treatment | 18 (7.8) | 16 (27) | 17.5 (12.8) | 15.5 (25.8) |
| baseline to 3 months | 15.5 (33.8) | 15 (33.8) | 14.4 (14.3) | 15.4 (31.3) |
| baseline to 6 months | 12 (10.5) | 19.5 (25.8) | 11.5 (17.3) | 16.5 (30.8) |
| Total change score SF36 PCS | ||||
| baseline to post treatment | -8.9 (13.9) | -.9 (18.4) | -7.5 (14.6) | -0.5 (13.7) |
| baseline to 3 months | -15.8 (18.4) | -2.1 (16) | -12.3 (14.2) | -1.6 (17.4) |
| baseline to 6 months | -10.5 (13.3) | -3.80 (18.8) | -10.2 (10.2) | -4.6 (17.5) |
| Total change score SF36 MCS | ||||
| baseline to post treatment | -4.9 (8.1) | -1 (16.9) | -2.1 (8.5) | -1 (11.9) |
| baseline to 3 months | -5.7 (18.2) | +1.6 (13.9) | -0.3 (16.7) | +1.6 (13.3) |
| baseline to 6 months | -7.2 (16.2) | -4.4 (21.6) | -2.3 (15.9) | -2.9 (10.1) |